Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.10
    +1.92 (+7.33%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    UroGen Pharma Ltd (URGN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    UroGen Pharma (URGN) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, UroGen Pharma reported EPS of -$0.03, below the $0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    37%(14/38)
    Avg Surprise
    -7.75%

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.46
    Range$0.13 - $0.69
    9 analysts
    Revenue Consensus
    $109.24M
    Range$93.24M - $119.70M
    9 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.32
    Range$0.01 - $0.68
    5 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.42-23.6%
    60d ago$0.42-23.6%
    30d ago$0.42-23.6%
    7d ago$0.39-16.7%
    Current$0.32
    Revenue Consensus
    $114.50M
    Range$103.50M - $128.70M
    4 analysts

    Next Report

    URGN has an expected report date of Mar 1, 2027.

    URGN Earnings Call

    The latest URGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, URGN beat 14, missed 23 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $89.00M, up 223.9% from $27.48M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.03$0.05-$0.07 - $0.19-160.00%MissN/A65 up, 0 downNov 4, 2026$89.00M
    Jun 30, 2026-$0.28-$0.38-$0.61 - -$0.16+26.32%BeatN/A85 up, 0 downAug 5, 2026$72.46M
    Mar 31, 2026-$0.47-$0.48-$0.62 - -$0.11+2.08%BeatN/A82 up, 0 downMay 6, 2026$50.96M
    Dec 31, 2025-$0.53-$0.48-$0.74 - -$0.31-9.94%MissN/A70 up, 1 downMar 2, 2026$37.84M
    Sep 30, 2025-$0.69-$0.68-$0.79 - -$0.52-1.47%MissN/A70 up, 4 downNov 6, 2025$27.48M
    Jun 30, 2025-$1.05-$0.82-$0.94 - -$0.60-28.05%MissN/A71 up, 3 downAug 7, 2025$24.21M
    Mar 31, 2025-$0.92-$0.79-$0.96 - -$0.37-16.46%MissN/A61 up, 2 downMay 12, 2025$20.25M
    Dec 31, 2024-$0.80-$0.72-$0.97 - -$0.55-11.11%MissN/A70 up, 1 downMar 10, 2025$24.57M
    Sep 30, 2024-$0.55-$0.82-$0.91 - -$0.76+32.93%BeatN/A70 up, 0 downNov 6, 2024$25.20M
    Jun 30, 2024-$0.91-$0.83-$0.90 - -$0.77-9.64%MissN/A51 up, 0 downAug 13, 2024$21.85M
    Mar 31, 2024-$0.97-$0.87-$0.99 - -$0.75-11.49%MissN/A51 up, 0 downMay 13, 2024$18.78M
    Dec 31, 2023-$0.72-$0.68-$0.74 - -$0.61-5.88%MissN/A50 up, 0 downMar 14, 2024$23.53M
    Sep 30, 2023-$0.68-$0.87-$0.96 - -$0.73+21.84%BeatN/A50 up, 0 downNov 14, 2023$20.85M
    Jun 30, 2023-$1.03-$1.14-$1.18 - -$1.11+9.65%BeatN/A50 up, 1 downAug 10, 2023$21.14M
    Mar 31, 2023-$1.30-$1.24-$1.77 - -$1.21-4.84%MissN/A60 up, 0 downMay 11, 2023$17.19M
    Dec 31, 2022-$1.22-$1.07-$1.42 - -$0.89-14.02%MissN/A60 up, 0 downMar 16, 2023$18.09M
    Sep 30, 2022-$1.13-$1.14-$1.69 - -$1.03+0.88%BeatN/A60 up, 0 downNov 10, 2022$16.10M
    Jun 30, 2022-$1.18-$1.33N/A+11.28%BeatN/AN/A1 up, 0 downAug 11, 2022$16.60M
    Mar 31, 2022-$1.25-$1.25-$1.58 - -$1.180.00%In lineN/A60 up, 0 downMay 10, 2022$13.56M
    Dec 31, 2021-$1.27-$1.17-$1.39 - -$1.05-8.55%MissN/A60 up, 0 downMar 21, 2022$16.17M
    Sep 30, 2021-$1.35-$1.33-$1.42 - -$1.10-1.50%MissN/A6N/ANov 15, 2021$11.35M
    Jun 30, 2021-$1.17-$1.09-$1.32 - -$0.95-7.34%MissN/A5N/AAug 4, 2021$13.03M
    Mar 31, 2021-$1.17-$1.25-$1.49 - -$0.84+6.40%BeatN/A8N/AMay 13, 2021$7.49M
    Dec 31, 2020-$1.38-$1.37-$1.84 - -$1.19-0.73%MissN/A8N/AMar 18, 2021$7.97M
    Sep 30, 2020-$1.31-$1.47-$1.59 - -$1.38+10.88%BeatN/A8N/ANov 9, 2020$3.46M
    Jun 30, 2020-$1.44-$1.52-$1.75 - -$1.08+5.26%BeatN/A9N/AAug 10, 2020$372000
    Mar 31, 2020-$1.79-$1.62-$1.90 - -$1.40-10.49%MissN/A9N/AMay 7, 2020N/A
    Dec 31, 2019-$1.86-$1.70-$1.85 - -$1.55-9.41%MissN/A9N/AMar 2, 2020N/A
    Sep 30, 2019-$1.06-$1.28-$1.42 - -$1.17+17.19%BeatN/A8N/ANov 12, 2019N/A
    Jun 30, 2019-$1.08-$1.20-$1.33 - -$1.11+10.00%BeatN/A9N/AAug 9, 2019$18000
    Mar 31, 2019-$1.11-$1.26-$1.31 - -$0.59+11.90%BeatN/A7N/AMay 9, 2019N/A
    Dec 31, 2018-$1.46-$1.24-$1.46 - -$0.92-17.74%MissN/A7N/AFeb 28, 2019$845000
    Sep 30, 2018-$1.28-$1.11-$1.14 - -$0.92-15.32%MissN/A6N/ANov 12, 2018$283000
    Jun 30, 2018-$1.14-$0.93-$1.00 - -$0.80-22.58%MissN/A5N/AAug 14, 2018$364000
    Mar 31, 2018-$0.88-$0.72-$0.84 - -$0.63-22.22%MissN/A5N/AMay 15, 2018$481000
    Dec 31, 2017-$0.74-$0.64-$0.69 - -$0.41-15.63%MissN/A5N/AMar 15, 2018$327000
    Sep 30, 2017-$0.02$0.11N/A-118.18%MissN/AN/AN/ANov 14, 2017$7.81M
    Jun 30, 2017-$0.68-$1.77N/A+61.58%BeatN/AN/AN/AAug 14, 2017$7.81M
    Mar 31, 2017-$1.11N/AN/AN/AN/AN/AN/AN/AMay 5, 2017$19000
    Last 39 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.19, after -$3.23 the year before. It was -$2.55 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.19N/A
    Dec 31, 2024-$3.23N/A
    Dec 31, 2023-$3.73N/A
    Dec 31, 2022-$4.78N/A
    Dec 31, 2021-$4.96N/A
    Dec 31, 2020-$5.92N/A
    Dec 31, 2019-$5.11N/A
    Dec 31, 2018-$4.76N/A
    Dec 31, 2017-$2.55N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,03812
    2026Q2Jun 30, 20265,43713
    2026Q1Mar 31, 20265,50012
    2025Q4Dec 31, 20256,39212
    2025Q3Sep 30, 20256,20013
    2025Q2Jun 30, 20256,31712
    2025Q1Mar 31, 20255,80813
    2024Q4Dec 31, 20246,42912

    2026Q3 Earnings Call

    Opening remarks

    Vincent I. Perrone Senior Director of Investor Relations Thank you. Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2026 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2026. The release can be accessed on the Investors portion of our website at investors.urogen.com. Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Christopher Degnan, Chief Financial Officer. On today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to ZUSDURI and Jelmyto; our ongoing and planned clinical trials and nonclinical studies; commercial and clinical development milestones; market and revenue opportunities; our commercialization strategy and expectations; anticipated data, regulatory filings and decisions; the importance of ZUSDURI's growth for UroGen's long-term strategy; anticipated benefits of our strategic collaboration with IntraGel Therapeutics; the potential benefits of our products and product candidates; future R&D efforts and milestones; our corporate goals; and 2026 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements. I will now turn the call over to Liz Barrett, Chief Executive Officer. Liz?

    Elizabeth A. Barrett Chief Executive Officer Good morning, and thank you for joining us today. We delivered another quarter of strong execution, with ZUSDURI generating $68 million in net product revenue, representing 35% sequential quarter-over-quarter growth. More importantly, the underlying commercial trends continue to strengthen, with increasing repeat utilization, broader physician adoption, and continued expansion into community practices. Together, these trends reinforce our confidence that ZUSDURI is scaling successfully and establishing a strong foundation for sustained growth. This momentum reflects the product's differentiated value proposition. As the first and only FDA-approved medicine for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, ZUSDURI offers a primary surgery-free alternative for a disease that historically has been managed through repetitive surgical interventions. We believe this differentiated approach provides patients an opportunity to have more recurrence-free and treatment-free living, and is increasingly changing how physicians think about treating these patients. Turning to the operating metrics, as of September 30, 2026, we had over 1,500 activated accounts. With a substantial foundation of activated accounts now in place, our commercial team's focus is shifting toward driving utilization within these practices, converting new prescribers into repeat users, and expanding adoption across the broader physician community.

    Frequently Asked Questions About URGN

    When is UroGen Pharma's next earnings date?

    UroGen Pharma's next earnings report is expected for Mar 1, 2027.

    Did URGN beat earnings estimates last quarter?

    No. UroGen Pharma reported EPS of -$0.03 for the quarter ended Sep 30, 2026, below the $0.05 estimate by 160.00%.

    What EPS do analysts expect from URGN next quarter?

    The consensus EPS estimate for UroGen Pharma for the quarter ending Dec 31, 2026 is $0.46 from 9 analysts, with estimates from $0.13 to $0.69.

    How often does URGN beat earnings estimates?

    UroGen Pharma beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -24.83%.